TrialThe Lancet. Infectious diseases2023

Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trial.

Shabir A Madhi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.